CERTARA®

Accelerating Medicines, Together

Disclaimer

Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.

Trademarks and Service Marks

The Certara design logo, "Certara," and our other registered or common law trademarks, service marks or trade names appearing in this presentation are our property. Solely for convenience, our trademarks, tradenames, and service marks referred to in this presentation appear without the registered mark or trademark symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, tradenames, and service marks. This presentation contains additional trademarks, tradenames, and service marks of other companies that are the property of their respective owners. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, that reflect the Company's current views with respect to, among other things, the Company's operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "suggest," "plan," "believe," "intend," "project," "forecast," "estimates," "targets," "projections," "should," "could," "would," "may," "might," "will," and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company's ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange fluctuation and adverse developments in the financial services industry; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers, and the other factors detailed under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and elsewhere in our Securities and Exchange Commission ("SEC") filings and reports, including the Annual Report on Form 10-K filed with the SEC on February 29, 2024. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and is expressly qualified in its entirety by the cautionary statements included in this presentation. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on our forward-looking statements.

Non-GAAP Financial Information

This presentation contains "non-GAAP measures" that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, we make use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted diluted earnings per share ("EPS"), and constant currency ("CC") revenue, which are not recognized terms under GAAP and should not be considered as alternatives to net income (loss), GAAP EPS, or GAAP revenue as measures of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. These non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

Adjusted EBITDA represents net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, acquisition and integration expense and other items not indicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. Adjusted net income and adjusted diluted EPS exclude the effect of the same items noted above with respect to adjusted EBITDA from GAAP net income (loss) and GAAP EPS, respectively, as well as adjust the provision for income taxes for such charges. CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. dollars are converted into U.S. dollars at the average exchange rates in effect for the comparable prior periods. You should refer to the appendix at the end of this document for a reconciliation of these non-GAAP measures in specific periods to their most directly comparable financial measures calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income from operations, net income, CC revenue and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company's business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company's performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company's business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance. Management believes that these metrics are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance. In addition, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We use CC revenue to evaluate the underlying performance of the business, and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance. In evaluating adjusted EBITDA, adjusted net income (loss), adjusted diluted EPS, and CC revenue, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

Our Mission

We accelerate medicines to patients
using biosimulation software, technology and services
to transform traditional drug discovery and development.

CERTARA

Certara at a Glance

BUSINESS[1]

20+ Year
History of innovation

~1,400 Employees

430+ with Ph.D.s, Pharm.D.s and M.D.s

20 Acquisitions
Track record of accretive, complementary acquisitions

END-TO-END PLATFORM

Software

- Biosimulation
- Regulatory & compliance
- Market access

Technology-Driven Services

- Drug discovery & development with biosimulation
- Regulatory science
- Market access

$14B TAM growing at **8-17%** CAGR[2]

CUSTOMERS[3]

~2,400
Customers across 66 countries

10+ Year
Average tenure for top 30 customers

389 customers with ACV > $100,000

63 customers with ACV > $1M

1Q 2024 FINANCIALS

$**96.7M** Revenue

7% GAAP YoY Growth
6% CC YoY Growth[4]

Net Income (**$4.7M**)
PY $1.4M

$29.1M
Reported Adjusted EBITDA[5]
PY $32.3M

30% Adjusted EBITDA Margin[5]

(1) As of 12/31/2023
(2) Market research reports from Grand View and SpendEdge; as of 2024
(3) Customer data as of 12/31/2023
(4) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)
(5) See Appendix for reconciliation of net income (loss) to adjusted EBITDA

CERTARA

Biosimulation is transforming traditional drug R&D

Traditional R&D Pain Points

- On average, it takes more than **10 years and $2B** to bring a drug to market[1]
- The probability of success of compounds entering **Phase I trials is only 7%[2],** and even in **Phase III, just 53%[3]** of drugs reach the market
- ~70% of drugs that failed in Phase II or Phase III trials[4] **failed due to safety and efficacy issues**

Benefits of Biosimulation

- ***In silico* trials can replace human clinical trials** in certain cases, saving significant time and money
- Biosimulation helps to **increase probability of success in human clinical trials**, the most expensive part of drug development
- Biosimulation helps to **optimize dosing for different populations** for enhanced safety and efficacy

Biosimulation can deliver significant time and cost savings in drug discovery and development

1. Biopharmaceutical Research and Development: The Process Behind New Medicines. www.PhRMA.org, January 2012, Washington, US http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
2. Dowden, H. et al. Trends in clinical success rates and therapeutic focus. *Nature Reviews Drug Discovery* 18, 495-496 (2019)
3. EvaluatePharma. World Preview. 2020
4. Harrison, R. Phase II and phase III failures: 2013 – 2015. *Nat Rev Drug Discov* 15, 817-818 (2016). https://doi.org/10.1038/nrd.2017.184

CERTARA

Biosimulation utilizes virtual patients to conduct *in silico* trials

Biosimulation is the computer-aided mathematical modeling of biological processes and systems to simulate and predict how the body affects the drug and how the drug affects the body

Simcyp Advanced Models for 10 Organs



Biosimulation Software Applications

- First-in-Human Dosing
- Drug-Drug Interactions
- Clinical Study Design
- Pediatric Dosing
- Bioequivalence
- Formulation
- Renal Impairment
- Hepatic Impairment
- Reduced Cardiac Output
- Food Effect

We have created 29 different virtual patient populations and mathematical models for 10 organs

CERTARA

Growing industry and regulatory adoption of biosimulation

Number of Scientific Publications on Biosimulation



Increased Incorporation of Biosimulation with FDA Guidance[2]

30+ FDA Guidances to Date



1. Science Direct search for publications by key search terms
2. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations. Wang et al. Clinical Pharmacology and Therapeutics, April 2019

CERTARA

Simcyp software has informed 300+ labels for 100 novel drug approvals

ONCOLOGY	Agios — Tibsovo *(ivosidenib)*	Genentech — Cotellic *(cobimetinib)*	Novartis — Rydapt *(midostaurin)*
	Amgen — Blincyto *(blinatumomab)*	Genentech — Polivy *(polatuzumab vedotin-piiq)*	Novartis — Tabrecta *(capmatinib)*
	Amgen — Lumakras *(sotorasib)*	Genentech — Rozlytrek *(entrectinib)*	Novartis — Zykadia *(ceritinib)*
	Ariad — Alunbrig *(brigatinib)*	Incyte — Pemazyre *(pemigatinib)*	Novartis — Jakavi *(ruxolitinib)*
	Ariad (Takeda) — Iclusig *(ponatinib)*	Janssen — Balversa *(erdafitinib)*	Pfizer — Bosulif *(bosutinib)*
	AstraZeneca — Calquence *(acalabrutinib)*	Janssen — Erleada *(apalutamide)*	Pfizer — Lorbrena *(lorlatinib)*
	AstraZeneca — Lynparza *(olaparib)*	Lilly — Retevmo *(selpercatinib)*	Pharmacyclics — Imbruvica *(ibrutinib)*
	AstraZeneca — Tagrisso *(osimertinib)*	Lilly — Verzenio *(abemaciclib)*	Sanofi — Jevtana *(cabazitaxel)*
	Beigene — Brukinsa *(zanubrutinib)*	Loxo Oncology — Vitrakvi *(larotrectinib)*	Seattle Genetics — Tukysa *(tucatinib)*
	BluePrint Medicines — Ayvakit *(avapritinib)*	Mirati — Krazati *(adagrasib)*	Spectrum — Beleodaq *(belinostat)*
	Celgene — Inrebic *(fedratinib hydrochloride)*	Novartis — Farydak *(panobinostat)*	Takeda — Exkivity *(mobocertinib)*
	Daiichi Sankyo — Turalio *(pexidartinib)*	Novartis — Kisqali *(ribociclib succinate)*	Taiho — Lytgobi *(futibatinib)*
	Eisai — Lenvima *(lenvatinib)*	Novartis — Scemblix *(asciminib)*	Verastem — Copiktra *(duvelisib)*
	EMD Serono — Tepmetko *(tepotinib hydrochloride)*	Novartis — Odomzo *(sonidegib)*	
	Genentech — Alecensa *(alectinib)*	Novartis — Vijoice *(alpelisib)*	
RARE DISEASE	AkaRx (Eisai) — Doptelet *(avatrombopag maleate)*	Intercept — Ocaliva *(obeticholic acid)*	PTC Therapeutics — Emflaza *(deflazacort)*
	AstraZeneca — Koselugo *(selumetinib)*	Kadmon — Rezurock *(belumosudil)*	Sanofi Genzyme — Cerdelga *(eliglustat tartrate)*
	Aurinia — Lupkynis *(voclosporin)*	Merck — Welireg *(belzutifan)*	Vertex — Symdeko *(tezacaftor/ivacaftor)*
	Genentech — Enspryng *(satralizumab)*	Mirum — Livmarli *(maralixibat)*	Vertex — Trikafta *(elexacaftor/ivacaftor/tezacaftor)*
	Genentech — Evrysdi *(risdiplam)*	Mitsubishi Tanabe — Dysval *(valbenazyne)*	
	Global Blood Therapeutics — Oxbryta *(voxelotor)*	Novartis — Isturisa *(osilodrostat)*	
CENTRAL NERVOUS SYSTEM	AbbVie — Rinvoq *(upadacitinib)*	Eisai — Dayvigo *(lemborexant)*	Lilly — Reyvow *(lasmiditan succinate)*
	AbbVie — Qulipta *(atogepant)*	Idorsia — Quviviq *(daridorexant)*	Novartis — Mayzent *(siponimod fumaric acid)*
	Alkermes — Aristada *(aripiprazole lauroxil)*	Janssen — Ponvory *(ponesimod)*	UCB — Briviact *(brivaracetam)*
	Alkermes — Lybalvi *(olanzapine/samidorphan)*	Kyowa Kirin — Nourianz *(istradefylline)*	
INFECTIOUS DISEASE	Gilead — Veklury *(remdesivir)*	Merck — Prevymis *(letermovir)*	Tibotec — Edurant *(rilpivirine)*
	Janssen — Olysio *(simeprevir)*	Nabriva — Xenleta *(lefamulin acetate)*	ViiV — Cabenuva Kit *(cabotegravir/rilpivirine)*
	Merck — Pifeltro *(doravirine)*	Novartis — Egaten *(triclabendazole)*	
GASTROENTEROLOGY	AstraZeneca — Movantik *(naloxegol)*	Phathom — Voquezna TriplePak *(vanoprazan/amoxicillin/clarithromycin)*	Shire — Motegrity *(prucalopride)*
	Helsinn — Akynzeo *(fosnetupitant/palonosetron)*	Shionogi — Symproic *(naldemedine)*	
CARDIOVASCULAR	Actelion (J & J) — Opsumit *(macitentan)*	BMS — Camzyos *(mavacamten)*	Pfizer — Revatio *(sildenafil)*
	Bayer (and Merck) — Verquvo *(vericiguat)*	Johnson & Johnson — Xarelto *(rivaroxaban)*	
OTHER	AbbVie — Orilissa *(elagolix)*	Janssen — Invokana *(canagliflozin)*	Merck — Steglatro *(ertugliflozin)*
	Agios — Pyrukynd *(mitapivat)*	Lilly — Olumiant *(baricitinib)*	Peloton/Merck — Welireg *(belzutifan)*
	Galderma — Aklief *(trifarotene)*	Lilly — Mounjaro *(tirzepadide)*	Takeda — Livtencity *(maribavir)*

Updated Feb. 2023

We believe that our customers would have faced *millions in additional costs and significant launch delays* had they conducted human clinical trials for these drug label claims

CERTARA

Blue chip customer base spanning large biopharma and biotech

Select Customers

Abbott, astellas, AstraZeneca, Biogen, Eisai, gsk, Lilly, MERCK, Pfizer, SANOFI, Sumitomo Dainippon Pharma, VERTEX, ARVINAS, biohaven pharmaceuticals, clarus THERAPEUTICS, GALDERMA, GRÜNENTHAL, idorsia, Incyte, LEO, Lundbeck, Medicines Development for Global Health, Mitsubishi Tanabe Pharma, NEKTAR, ono, Otsuka, SHIONOGI INC., TAISHO PHARMACEUTICAL, ucb

Number of FDA Approvals Since 2014



*Excludes diagnostics
Orphan designation applies across therapeutic areas

We have nearly 2,400 customers worldwide across 66 countries, including 38 of the top 40 biopharmaceutical companies by R&D spend in 2022

CERTARA

The Certara End-to-End Platform



For over 20 years, we have purpose-built and invested in our proprietary end-to-end platform with strategic acquisitions and innovation

1. As of 12/31/2023

CERTARA

Our end markets are large and growing



- **Drastic need for digital transformation** in $212B biopharma R&D market[1]
- Industry is in paradigm shift, with **biosimulation adoption accelerating** and increasing acceptance from regulatory agencies
- Technology and analytics-driven improvements **continue to grow exponentially** in Life Sciences

1. As of 2024

Sources: Grand View Research, SpendEdge

We use biosimulation and technology throughout R&D to reduce costs and improve outcomes

CERTARA

Biosimulation TAM Segmentation

Biosimulation TAM
$4.0B

Biosimulation Software ~50% Scientists at global pharmaceutical companies, mid-tier pharma, biotechs and CROs		Biosimulation Services ~50% Drug R&D programs	
Drug Discovery ~45%	**Drug Development** ~55%	**Drug Discovery** ~20%	**Drug Development** ~80%
Certara Solutions *(illustrative examples)*			
• Quantitative Systems Pharmacology (QSP) ○ *Immuno-oncology QSP* ○ *Immunogenicity QSP* • Discovery Informatics ○ *D360 Software*	• PBPK[1] ○ *Simcyp Simulator* • PK/PD[2] ○ *Phoenix Software* • Model-based meta-analysis ○ *CODEx Databases*	• QSP Consulting	• PBPK Consulting • PK/PD analysis • Model-based meta-analysis

1 Physiologically-based pharmacokinetic (PBPK)

2 Pharmacokinetic/pharmacodynamic (PK/PD)

CERTARA

Differentiated scientific and technology expertise

	Software	Tech-driven Services
Key Differentiators	✓ **Industry standard** built over 20 years ✓ Adopted by **23 global regulatory agencies** ✓ Embedded in customers' R&D processes – **105%+ net retention rate** ✓ Validated by **34k+ scientific publications** ✓ Used by **~400 academic institutions** ✓ **10+ year average tenure** for top 30 customers	✓ **Scalable service model** powered by proprietary technology ✓ High **net revenue repeat rate of 96%** in 2023 ✓ Integrated services with **90% of our top 50 customers using both biosimulation solutions and regulatory & access services** ✓ Renowned for **key opinion leadership** ✓ Depth and breadth of experience across every therapeutic area and modality

Our differentiated strengths enable us to win new customers and projects

CERTARA

Deeply experienced leadership team and global talent footprint

~420 **Scientists**

~230 **Regulatory Experts**

~100 **Market Access Specialists**

~220 **Software Developers & Technologists**



Of our ~1,400 employees, 430+ hold PhD, PharmD, or MD degrees

CERTARA

Certara's Industry-Standard Software

Biosimulation

Simcyp

Leading mechanistic biosimulation platform used to predict how drugs work, without human or animal studies

Phoenix

Industry-leading software for PK/PD, toxico-kinetic, and non-compartmental analyses – required for regulatory submissions

D360

Integrated informatics platform with self-service access and analytics to help manage discovery projects

CODEx

55 proprietary databases for meta-analysis of a new drug's safety and efficacy relative to other products

Regulatory & Market Access

GlobalSubmit

BaseCase

PINNACLE 21

Synchrogenix™ Writer

Cloud-based software to manage regulatory compliance and submissions and value communication

Certara Integral Repository

Our industry-leading software is adopted by more than 57,000 users worldwide across 66 countries

All statistics are as of 12/31/2023 unless noted

Certara's platform is built to meet clients where they are



CERTARA

Our R&D framework advances innovation in biosimulation

- **Consortia** collaboration
- User group meetings
- Scientific Advisory Board
- **1,000+** scientific customer projects per year



- Collaboration with **120+** academic institutions
- **5,000+** peer-reviewed articles
- **34,000** Google Scholar citations

- Regulatory guidances
- Regulatory workshops
- Regulatory meetings for customer programs

- **29** virtual populations
- **18,000+** peer-reviewed manuscripts
- **8,000+** studies in our databases

We have a regular cadence of incremental and breakthrough innovations with new software applications and updates

CERTARA

Our proven growth strategy

Innovation

Technology leader with **105%+ net retention rate**

Land and Expand

Significant white space to **expand** with customers and **add new** ones

M&A

20 successful strategic acquisitions, **13 with software**

Global Expansion

Track record of **mid-teens** topline growth with EBITDA margins in **mid- to high-30s**

People

An employer of choice, attracting **leading experts**

CERTARA

Long history of innovation driven by investment in our platform

Product Innovation



Well-positioned to continue delivering growth through organic and inorganic opportunities

CERTARA

Certara Financial Highlights

- Predictable bookings drive substantial revenue growth
- Highly recurring revenue driven by strong retention rates supports significant visibility
- Robust margins with attractive free cash flow conversion
- Investment in platform to drive future growth opportunities
- Long term potential for accelerated adoption of biosimulation solutions

CERTARA

Our Business Models

	Software	Tech-Driven Services
Products	• Simcyp • Phoenix • D360 • CODEx • GlobalSubmit • BaseCase • Pinnacle 21 • Integral	• Biosimulation • Regulatory Science • Market Access
Contract Type	Individual or bundled licenses depending on customer	Master Services Agreement or project specific
Contract Term	1 – 3 years	Project and program dependent
Recurring Revenue[1]	Net Retention Rate 109%	Net Revenue Repeat Rate 96%
% of Revenue[1]	37%	63%

1. Data as of 12/31/2023

Environmental, Social and Governance (ESG)

Certara Inaugural ESG Report

Issued April 2022

- **Accelerating crucial medicines to patients**
- **Advancing scientific thought leadership and knowledge sharing**
- **Increasing engagement with employees**

$28.1M
2021 R&D SPEND (10% OF REVENUE)

10
NEW PRODUCTS AND PRODUCT UPDATES IN 2021

1,200+
DRUG PROGRAMS ADVANCED IN 2021

250+
REGULATORY SUBMISSIONS IN THE PAST 4 YEARS

IN THE **top 25%**
IN ENGAGEMENT EMPLOYEE NET PROMOTER SCORE AMONG LIFE SCIENCE COMPANIES IN 2021

150+
SCIENTIFIC PUBLICATIONS, POSTERS AND PRESENTATIONS IN 2021

3,000+
SCIENTISTS TRAINED IN OUR SOFTWARE IN 2021

GENDER AND ETHNICALLY DIVERSE REPRESENTATION

GLOBAL FEMALE TALENT REPRESENTATION	FY20	FY21
FEMALE EMPLOYEES	52%	54%
FEMALE MANAGERS AND ABOVE	46%	48%
FEMALE NEW EMPLOYEE HIRES	55%	60%

U.S. ETHNICALLY DIVERSE TALENT REPRESENTATION	FY20	FY21
ETHNICALLY DIVERSE	27%	28%
ETHNICALLY DIVERSE MANAGERS AND ABOVE	22%	22%
ETHNICALLY DIVERSE NEW EMPLOYEE HIRES	34%	35%

CERTARA

We have a deeply experienced leadership team

William F. Feehery, PhD
Chief Executive Officer

DuPont · BCG · West

John Gallagher
Chief Financial Officer

cue · BD

Leif E. Pedersen
President, Chief Commercial Officer

Dassault Systèmes · Siemens · Oracle

Patrick F. Smith
President, Drug Development Solutions

Roche

Robert Aspbury, PhD
President, Certara Scientific Software

Covance

Max Kanevsky
Chief Technology Officer

P21 · R

Jaap Mandema, PhD
Chief Innovation Officer

Pharsight · alza

Amin Rostami, PhD
Chief Scientific Officer

simCYP · Manchester 1824 The University of Manchester

Nicolette Sherman
Chief Human Resources Officer

Oyster Point · Sanofi

Sheila Rocchio
Chief Marketing Officer

PHT

Ron DiSantis
SVP, Corporate Development

IQVIA · Vishay

Richard M. Traynor
General Counsel

EDGE Therapeutics · LifeCell · Jenkens & Gilchrist · Porzio Bromberg & Newman P.C.

Certara investment highlights

- Attractive end markets growing in mid-teens driven by R&D efficiency demand and global adoption
- Technology leader with highly predictable business model with 105%+ net retention rates
- Deeply embedded scientific solutions at the core of R&D with ~2,400 customers
- Significant opportunities to expand within customer base and add new customers worldwide
- Proven track record of innovation and 20 successful strategic acquisitions
- Long track record of growth and profitability with 35%+ EBITDA margins and strong free cash flow

CERTARA

Covering Analysts

Bank	Analyst
Baird	Joe Vruwink
Bank of America	Michael Ryskin
Barclays	Luke Sergott
Jefferies	David Windley
JMP Securities	Constantine Davides
KeyBank	Scott Schoenhaus
Leerink	Michael Cherny
Morgan Stanley	Vikram Purohit
Stephens	Jeff Garro
UBS	Dan Leonard
William Blair	Max Smock

CERTARA®

Accelerating Medicines

Reconciliation of Net Income (Loss) to Adjusted EBITDA

	THREE MONTHS ENDED MARCH 31,	
	2024	2023
	(in thousands)	
Net income (loss)(a)	$ (4,683)	$ 1,358
Interest expense(a)	5,751	5,475
Interest income(a)	(2,574)	(1,354)
(Benefit from) Provision for income taxes(a)	(751)	1,111
Depreciation and amortization expense(a)	432	411
Intangible asset amortization(a)	15,996	13,113
Currency (gain) loss(a)	876	894
Equity-based compensation expense(b)	9,073	8,543
Change in fair value of contingent consideration(d)	2,878	1,261
Acquisition-related expenses(e)	1,714	1,192
Integration expense(f)	—	102
Reorganization expense(g)	51	—
Loss on disposal of fixed assets(h)	—	4
Executive recruiting expense(i)	380	196
Adjusted EBITDA	$ 29,143	$ 32,306

Reconciliation of Revenues to the Revenues Adjusted for Constant Currency

	THREE MONTHS ENDED MARCH 31,			Change			
	2024	2024	2023	$	%	$	%
	Actual (GAAP)	CC (non-GAAP)	Actual (GAAP)	Actual (GAAP)	Actual (GAAP)	CC Impact (non-GAAP)	(non-GAAP)
	(in thousands except percentage)						
Revenue							
Software	$ 39,307	$ 39,015	$ 33,004	$ 6,303	19%	$ (292)	18%
Services	57,347	57,038	57,297	50	—%	(309)	—%
Total Revenue	$ 96,654	$ 96,053	$ 90,301	$ 6,353	7%	$ (601)	6%

CERTARA

Notes to Reconciliations

(a.) Represents amounts as determined under GAAP.

(b.) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

(c.) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.

(d.) Represents expense associated with remeasuring fair value of contingent consideration of business acquisition.

(e.) Represents expense associated with goodwill impairment charge.

(f.) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.

(g.) Represents integration costs related to post - acquisition integration activities.

(h.) Represents costs associated with our public offerings that are not capitalized.

(i.) Represents charges for severance provided to former executives.

(j.) Represents expense related to reorganization, including legal entity reorganization and lease abandonment cost associated with the evaluation of our office space footprint.

(k.) Represents the gain/loss related to disposal of fixed assets.

(l.) Represents recruiting and relocation expenses related to hiring senior executives.

(m.) Represents the first-year Sarbanes-Oxley costs for accounting and consulting fees related to the Company's preparation to comply with Section 404 of the Sarbanes-Oxley Act, as well as implementation cost of adopting ASC 842.

(n.) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.

(o.) Represents dilutive shares or potentially dilutive shares that were excluded from the Company's GAAP diluted weighted average common shares outstanding because the Company had a reported net loss and therefore including these shares would have been anti-dilutive.

CERTARA®

Accelerating Medicines, Together